Vincent Lisa M, Adams David, Hess Richard A, Ziegler Shira G, Tsilou Ekaterini, Golas Gretchen, O'Brien Kevin J, White James G, Huizing Marjan, Gahl William A
Section on Human Biochemical Genetics, Medical Genetics Branch, NHGRI, NIH, 10 Center Drive, Bldg. 10, Rm 10C107, MSC1851, Bethesda, MD 20892-1851, USA.
Mol Genet Metab. 2009 Jul;97(3):227-33. doi: 10.1016/j.ymgme.2009.03.011. Epub 2009 Apr 2.
Hermansky-Pudlak syndrome (HPS) develops from defects in the biogenesis and/or function of lysosome-related organelles essential to membrane and protein trafficking. Of the eight known human subtypes, only HPS-1 and HPS-4 develop pulmonary fibrosis in addition to the general clinical manifestations of oculocutaneous albinism and bleeding diathesis. We identified HPS-1 in three unrelated patients from different regions of India, who presented with iris transillumination, pale fundi, hypopigmentation, nystagmus, decreased visual acuity, and a bleeding diathesis. Two of these patients carried the homozygous mutation c.398+5G>A (IVS5+5G>A) in HPS1, resulting in skipping of exon 5 in HPS1 mRNA. The third patient carried a novel homozygous c.988-1G>T mutation that resulted in in-frame skipping of HPS1 exon 12 and removes 56 amino acids from the HPS1 protein. Given the discovery of HPS-1 in an ethnic group where oculocutaneous albinism (OCA) is highly prevalent, it is possible that HPS in India is under-diagnosed. We recommend that unconfirmed OCA patients in this ethic group be considered for mutational screening of known HPS genes, in particular c.398+5G>A and c.980-1G>T, to ensure that patients can be monitored and treated for clinical complications unique to HPS.
赫尔曼斯基-普德拉克综合征(HPS)是由对膜和蛋白质运输至关重要的溶酶体相关细胞器的生物发生和/或功能缺陷引起的。在已知的八种人类亚型中,只有HPS-1和HPS-4除了有眼皮肤白化病和出血素质的一般临床表现外,还会发展为肺纤维化。我们在来自印度不同地区的三名无关患者中鉴定出了HPS-1,他们表现为虹膜透照、眼底苍白、色素减退、眼球震颤、视力下降和出血素质。其中两名患者在HPS1中携带纯合突变c.398+5G>A(IVS5+5G>A),导致HPS1 mRNA中外显子5跳跃。第三名患者携带一种新的纯合c.988-1G>T突变,导致HPS1外显子12框内跳跃,并从HPS1蛋白中去除56个氨基酸。鉴于在眼皮肤白化病(OCA)高度流行的一个种族群体中发现了HPS-1,印度的HPS可能未得到充分诊断。我们建议对该种族群体中未经确诊的OCA患者进行已知HPS基因的突变筛查,特别是c.398+5G>A和c.980-1G>T,以确保能够对患者进行监测并针对HPS特有的临床并发症进行治疗。